

# CITATION REPORT

List of articles citing

## Dipeptidyl peptidase-4 inhibitors: 3 years of experience

DOI: 10.1089/dia.2011.0204

Diabetes Technology and Therapeutics, 2012, 14, 350-64.

**Source:** <https://exaly.com/paper-pdf/52543147/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
51	Unraveling oxyntomodulin, GLP1's enigmatic brother. <i>Journal of Endocrinology</i> , <b>2012</b> , 215, 335-46	4.7	94
50	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2581-91	4	21
49	New treatments for type 2 diabetes. <i>Medical Writing</i> , <b>2012</b> , 21, 279-283		
48	Vildagliptin added to metformin on $\beta$ cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 475-84	8.1	41
47	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and $\beta$ cell function. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2433-42	4	18
46	Alogliptin-Pioglitazone Combination Therapy: A Rational Approach to Treating Type 2 Diabetes Mellitus. <i>Combination Products in Therapy</i> , <b>2012</b> , 2, 1		2
45	[Oral antidiabetics: how you take the right choice]. <i>MMW Fortschritte Der Medizin</i> , <b>2012</b> , O 154 Suppl 2, 46-51; quiz 52	0	
44	Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, $\beta$ cell function and insulin resistance in type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , <b>2012</b> , 98, 51-60	7.4	54
43	Exenatide plus metformin compared with metformin alone on $\beta$ cell function in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2012</b> , 29, 1515-23	3.5	48
42	Treatment of diabetes using traditional Chinese medicine: past, present and future. <i>The American Journal of Chinese Medicine</i> , <b>2012</b> , 40, 877-86	6	120
41	Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. <i>Diabetes Therapy</i> , <b>2012</b> , 3, 10	3.6	38
40	$\alpha$ -Glucosidase inhibitors and their use in clinical practice. <i>Archives of Medical Science</i> , <b>2012</b> , 8, 899-906	2.9	194
39	Metformin and its clinical use: new insights for an old drug in clinical practice. <i>Archives of Medical Science</i> , <b>2012</b> , 8, 907-17	2.9	58
38	Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan. <i>Pharmaceutics</i> , <b>2012</b> , 4, 479-93	6.4	9
37	Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 1221-36	3.5	47
36	Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures. <i>Diabetes Therapy</i> , <b>2013</b> , 4, 269-83	3.6	7
35	Variation in inflammatory markers and glycemic parameters after 12-months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 817-26	5.8	19

34	RETRACTED: Evaluation of the positive effects on insulin-resistance and $\beta$ cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. <i>Pharmacological Research</i> , <b>2013</b> , 73, 20-6	10.2	17
33	Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119. <i>Journal of Medicinal Chemistry</i> , <b>2013</b> , 56, 301-19	8.3	27
32	Oral hypoglycemics in cats with diabetes mellitus. <i>Veterinary Clinics of North America - Small Animal Practice</i> , <b>2013</b> , 43, 407-15	2.4	5
31	Advances in pharmacologic therapies for type 2 diabetes. <i>Current Atherosclerosis Reports</i> , <b>2013</b> , 15, 302-6	6	13
30	A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. <i>Diabetes Technology and Therapeutics</i> , <b>2013</b> , 15, 214-22	8.1	14
29	A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and $\beta$ cell function: the triple oral therapy. <i>Diabetic Medicine</i> , <b>2013</b> , 30, 846-54	3.5	10
28	Sitagliptin: results from clinical practice. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 1483-5	2.5	2
27	Hypoglycemia, its implications in clinical practice, and possible ways to prevent it. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 771-3	2.5	4
26	Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor: an analysis of initial versus sequential combination therapy. <i>Postgraduate Medicine</i> , <b>2014</b> , 126, 47-55	3.7	
25	Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 957-67	12.7	23
24	Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. <i>Fundamental and Clinical Pharmacology</i> , <b>2014</b> , 28, 221-9	3.1	23
23	Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes. <i>Diabetic Medicine</i> , <b>2014</b> , 31, 1515-23	3.5	12
22	Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?. <i>Journal of Medicinal Chemistry</i> , <b>2014</b> , 57, 2197-212	8.3	136
21	Diabetes: safety and efficacy of albiglutide-results from two trials. <i>Nature Reviews Endocrinology</i> , <b>2014</b> , 10, 514-6	15.2	
20	Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 812-8	6.7	42
19	Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 1198-201	6.7	6
18	Sulfonylureas and their use in clinical practice. <i>Archives of Medical Science</i> , <b>2015</b> , 11, 840-8	2.9	220
17	Management of type 2 diabetes mellitus in chronic kidney disease. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 95-7	2.5	2

16	Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , <b>2015</b> , 35, 333-336		4
15	In Vitro and In Vivo Evaluation of Nanoparticles Prepared by Nano Spray Drying for Stomach Mucoadhesive Drug Delivery. <i>Drying Technology</i> , <b>2015</b> , 33, 1199-1209	2.6	18
14	Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. <i>Journal of Clinical Pharmacology</i> , <b>2015</b> , 55, 409-14	2.9	4
13	Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. <i>Lipids in Health and Disease</i> , <b>2016</b> , 15, 204	4.4	20
12	DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control. <i>Archives of Pharmacal Research</i> , <b>2016</b> , 39, 1114-28	6.1	36
11	Controversy of oral hypoglycemic agents in type 2 diabetes mellitus: Novel move towards combination therapies. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , <b>2017</b> , 11 Suppl 1, S5-S13	8.9	17
10	Glucose-lowering drugs. <b>2017</b> , 298-322		
9	The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	80
8	Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , <b>2019</b> , 18, 144	4.4	6
7	Design and synthesis of novel pyridazine N-aryl acetamides: In-vitro evaluation of $\alpha$ -glucosidase inhibition, docking, and kinetic studies. <i>Bioorganic Chemistry</i> , <b>2020</b> , 102, 104071	5.1	5
6	Anti-steatotic linagliptin pleiotropic effects encompasses suppression of de novo lipogenesis and ER stress in high-fat-fed mice. <i>Molecular and Cellular Endocrinology</i> , <b>2020</b> , 509, 110804	4.4	2
5	Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 1	10.5	0
4	Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Drug Research</i> , <b>2021</b> , 71, 477-488	1.8	1
3	Commentary on "Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus: International Task Force". <i>Indian Journal of Endocrinology and Metabolism</i> , <b>2018</b> , 22, 158-159	1.7	2
2	Therapeutic Experience of Saxagliptin as First Add-on after Metformin in Indian Type 2 Diabetes Patients: A Non-interventional, Prospective, Observational Study (ONTARGET-INDIA). <i>Indian Journal of Endocrinology and Metabolism</i> , <b>2019</b> , 23, 312-317	1.7	
1	Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: An insight on molecular approaches.. <i>Biotechnology Letters</i> , <b>2022</b> , 44, 203	3	0